SCHEMBL2401027

SCHEMBL2401027

CCC(C(=O)N1CCC2(CC1)CC(C(=O)NCCC#N)=NO2)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
TSHR P16473 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GAA P10253 1/20 0.43
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
RECQL P46063 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GPR119 Q8TDV5 2/20 0.38
CHRM1 P11229 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
ITGB3 P05106 1/20 0.34
ITGB1 P05556 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6411364 0.85 ALDH1A1 (0.46) ALDH1A1TSHRL3MBTL1GAAKDM4E
SCHEMBL2400919 0.83 ALDH1A1 (0.59) ALDH1A1TSHRL3MBTL1GAAKDM4E
SCHEMBL2581171 0.77 TP53 (0.49) ALDH1A1MAPK1
SCHEMBL6414864 0.75 ALDH1A1 (0.56) ALDH1A1TSHRL3MBTL1GAAKDM4E
SCHEMBL15309184 0.71 ALDH1A1 (0.61) ALDH1A1TSHRL3MBTL1GAAKDM4E
SCHEMBL2400339 0.70 ALOX15 (0.42) HSD17B10
SCHEMBL2400325 0.67 GPR119 (0.54) KDM4ELMNANPSR1GPR119JAK2
SCHEMBL2400949 0.66 CYP3A4 (0.50) ALDH1A1TSHRMAPK1
SCHEMBL2400415 0.65 MEN1 (0.46) ALDH1A1TSHRGAAKDM4EHSD17B10
SCHEMBL6417790 0.65 NPSR1 (0.53) TSHRKDM4ELMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US claimed
US-8048890-B2 Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents GRUENENTHAL GMBH (DE) 2011-11-01 US disclosed
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods GRUENENTHAL GMBH (DE) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224172-A1 Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods SULT1E1, DECR1, CYP8B1 ALDH1A1 156/4885TSHR 1894/4885L3MBTL1 4865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.